United States of America

In my mind, the biggest update in the Roundup lawsuit is that there expected settlement value keeps rising.  Here is what else is happening.

$289 Million Verdict Update

courthouse1-300x189During a hearing on October 24th after the whopping $289 million verdict against Monsanto,  a California trial judge issued a ruling reducing the verdict.  This case, as you probably know if you are reading this, involved a man who was diagnosed non-Hodgkin’s lymphoma a couple years after using Roundup several times a day while on the job as a school groundskeeper.  The judge reduced what was previously a $289 million settlement to $49 million.    The judge reduced the punitive damages to match the compensatory damages.

The Children’s Hospital of Philadelphia (CHOP) has been conducting a study on polyethylene glycol 3350 (PEG 3350), the active ingredient in MiraLAX, and its effect on a child’s brain. The study came about after reports that children have been experiencing behavioral problems after taking MiraLAX.

What is MiraLAX and how is it different?

MiraLAX is a laxative that. MiraLAX has branded itself as being different from other laxatives by having fewer side effects. The medication’s own website notes that it works with your body’s natural process to provide relief from constipation. It claims that working with the body prevents harsh side effects. This contrasts from stimulant laxative pills, which forcefully stimulates nerves in your colon.

This is just crazy.  It what appears to be a rerun of a rerun, the FDA has once again updated its recall list of valsartan-containing products. If you are currently taking Valsartan, you must check that list to see your medication may or may not be on it. If you are unaware of the previous valsartan recalls, please inform yourself as this will help you become more informed on how these medications may affect your overall health. You must also know about the lawsuits involving NDMA-contaminated valsartan, as it shows what kind of hardships people might experience after taking these tainted drugs.

  1. What was added to the recall list?

The FDA added valsartan-containing products under the brand name RemedyRepack to its recall list. Their tests determined that the valsartan brand contained N-nitrodimethylamine (NDMA), which is considered a carcinogen by both the Environmental Protection Agency (EPA) and the FDA. The pharmaceutical companies Prinston and Solco distribute this brand. Both Prinston and Solco are involved in class action lawsuits throughout the United States that involve their distribution of already recalled valsartan-containing products. This updated recall list highlights the extent of how many valsartan-containing products are contaminated.

If you have a Ethicon Physicomesh lawsuit, here are 8 things you want to know.

  1. Ethicon Physiomesh

The Physiomesh was introduced in 2010 and had an absorbable film coating on each side of the mesh. It was designed to minimize inflammation and incorporate the patch into the body. Ethicon, a subsidiary of Johnson & Johnson, manufactured the Physiomesh.

Window tints laws require a significant amount of light to be transmitted in car windows. Once pulled over, a police officer may check to see if your car’s window tints are legal or not. You may ask yourself how police officers can do that. In addition to knowing how to check for too much tint, you must know the window tint laws in both Maryland and D.C.

  1. How do the police determine if a window has too much tint?

The only way to determine if there is an actual violation of the statute is for the officer, after stopping the vehicle, to conduct a test utilizing a “two-piece window tint meter.” When observing a vehicle without the benefit of such a device there is no definitive way to determine if the window tint on a car is in violation of the statute other than by eyeballing it.

Recent findings from the Trial Assigning Individualized Options for Treatment (Rx), also known as the TAILORx trial, show that chemotherapy is not beneficial to the most commonly found form of breast cancer. Sponsored by the National Cancer Institute (NCI), researchers found that chemotherapy does not benefit 70 percent of women with estrogen receptor-positive, HER2-egnative, axillary lymph node-negative breast cancer. Hormone therapy combined with chemotherapy is not more beneficial than treating breast cancer with hormone therapy alone. Researchers released this data at the American Society of Clinical Oncology’s annual meeting this year in Chicago.

Details of the study

vaginal mesh tragediesBeginning in 2006, researchers conducted this study to examine the effectiveness of hormone therapy alone compared to using both hormone therapy and chemotherapy in treating breast cancer. The study divided women into two groups. The groups were based on the individual woman’s genes that determine their risk of cancer recurrence. This would be determined by a molecular test that examines their tumors. It is known as the Oncotype DX Breast Recurrence Score. The test examines 21 genes associated with breast cancer recurrence. Each participant’s tumors were analyzed using this test. They were each assigned a risk score that was on a scale from 0-100. The higher the score, the higher the recurrence risk. Women who had a score of 0-10 received hormone therapy only. Women who had a score of 26 and above were considered high-risk and given chemotherapy. Women who had a score of 11-25 were randomly assigned to receive just hormone therapy or hormone therapy and chemotherapy.

In October 2018, settlements in the AbbVies AndroGel lawsuits FINALLY appear ready to resolve.  The drug company and plaintiffs lawyers are dotting the i’s and crossing the t’s on a settlement agreement that would resolve thousands of testosterone cases.

Lawsuits had been filed claiming that the makers of Androgel, AbbVie, failed to warn thousands of men about the potential side-effects of the drug. These side-effects include heart attacks, blood clots, stroke, and even sudden death in extraordinary cases. As the litigationandrogel-lawsuit wheels are starting to turn here, AbbVie is trying to gum them up with objections to slow down the process.  You could say everything is going according to plan….

Androgel Lawsuits

If you are reading this you probably already know this but let’s recap where were are. Currently, there are about 7,000 lawsuits against AbbVie percolating around the federal court system. The various suits allege that the makers of Androgel, AbbVie, neglected to warn thousands of men about the serious side effects of the “Low-T” treatment drug. This drug has certainly been a big hit, understandably so considering that it promises men physical enhancement to counteract the forces of aging. But thousands of lawsuits -allege that low-T drugs can lead to heart attack, stroke, pulmonary embolism, deep vein thrombosis, or other injuries, prompting men across the U.S. to sue AbbVie and the other manufacturers for not being adequately warned of the risks.

That really is what this is about.  No one — at least not many people — are calling for a low-T recall.  The risk might outweigh the benefit for some although probably not many of us.  It is about giving patients and doctors a choice. Tell us what can happen and let us make the call.  They are giving this warning now.  They should have given it to us before.  That is what these lawsuits are about.

Continue reading

The gadolinium contrast class action lawsuits took a hit last week when the MDL Panel denied class certification which would have consolidated all of the federal court cases under one roof.  But I’m convinced there will be an MDL class action in the gadolinium contrast cases in the next year.  These deposition disease cases are still heating up in spite of this setback.

If you are a victim or a lawyer getting calls from clients, here are 7 things you need to know about the gadolinium contrast litigation.

  1. What are GBCAs?

  1. What is Zostavax?

Zostavax is a single shot vaccine that helps prevent herpes zoster, also known as the shingles. It is a weakened live form of the virus, meant to train the immune system to fight it off. Zostavax is primarily meant for individuals 50 years and older. Developed by the pharmaceutical company Merck & Company, the FDA approved it in 2006. It is a stronger version of Varivax, another shingles’ vaccine also developed by Merck.

  1. What are the shingles?

The Washington Post wrote an article Monday underscoring fact that is well-known to lawyers handling malpractice cases in Maryland: doctors struggle to accurately read tests that determine medical conditions. Unfortunately for patients, this can have serious long-term consequences.

Most of these errors do not lead to malpractice cases because they show false positives.  Sometimes these are malpractice cases because the unnecessary test is the harm — we tried that very case in Baltimore County last year and our client received a $1.45 million verdict.

Below are a few examples that I think really highlight the consequences of this problem.  Each of these following examples and studies highlights the need for us to find a path to help doctors to improve their ability to assess tests more accurately.